Filing Flows › Industrials › Illumina (ILMN)
Illumina (ILMN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 30, 2026 · Illumina (ILMN) Q3 2026 earnings results →
Q3 2026 Revenue up 4% year over year to $1.1B · 19¢ of every $1 of revenue kept as net profit · operating margin 27.0%
Illumina made $1.1B in Q3 2026 (+4% Y/Y): Total product revenue $946M, Service $183M. Operating margin 27.0%, net earnings $220M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 30, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.1B in Q3 2026, up 4% year over year and down 3% from the previous quarter. Consumables was the largest line at 74% of revenue. Service added $0.03B year over year (up 17%), 58% of the total change. Instruments declined 5%.
Gross margin was 73.5%, up 5.9 points from Q3 2025. Operating profit was $0.30B, a 27.0% margin (up 6.1 points year over year). Of the extra revenue versus Q3 2025, 173% reached operating profit, above the 21% margin then. Operating expenses grew 4% against revenue growth of 4%. Net earnings were $0.22B, up 47% year over year. The effective tax rate was 16.7%.
Operating cash flow was $0.42B (up 48% year over year), 190% of net earnings. Non-cash charges added back $0.07B of depreciation and amortization and $0.07B of share-based compensation. Working capital and other items added $0.05B. After purchases of property and equipment ($0.04B), free cash flow as the company reports it was $0.38B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 30, 2026 | $1.1B | +4% | 27.0% | $220M | $419M |
| Q2 2026 | 10-Q | Jul 31, 2026 | $1.2B | +9% | 21.1% | $207M | $201M |
| Q1 2026 | 10-Q | May 4, 2026 | $1.1B | +5% | 19.2% | $134M | $289M |
| Q4 2025 | 10-K | Feb 12, 2026 | $1.2B | +5% | 17.3% | $334M | $321M |
| Q3 2025 | 10-Q | Oct 31, 2025 | $1.1B | +0.4% | 20.9% | $150M | $284M |
| Q2 2025 | 10-Q | Aug 1, 2025 | $1.1B | -5% | 20.2% | $235M | $234M |
| Q1 2025 | 10-Q | May 9, 2025 | $1.0B | -3% | 15.8% | $131M | $240M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- NTRA · Stated in 10-K (named, share not stated) · source
- GH · Stated in 10-K (named, share not stated) · source
- FLGT · Stated in 10-K (named, share not stated) · source
- GRAL · Stated in 10-K (named, share not stated) · source
- CAI · Stated in 10-K (named, share not stated) · source
- TEM · Stated in 10-K (named, share not stated) · source
- WGS · Stated in 10-K (named, share not stated) · source
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
In its own words, from its 8-K, filed Jul 30, 2026.
Illumina against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +4% against the peers' median +4%. Operating margin: 27.0% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
| TXG 10x Genomics | Q3 2026 | $151M | +1% | -10.7% |
Source: Illumina 10-Q on SEC EDGAR · CIK 1110803 · Laboratory Analytical Instruments
Guidance and outlook
13F: who owns ILMN and who is buying
More on ILMN
- How Illumina makes money: revenue by segment
- Illumina next earnings date and what analysts expect
- Illumina stock forecast, price target and fair value
- Who owns Illumina stock: holders, funds and Congress trades
- Illumina guidance and outlook
- Is Illumina a takeover target? LBO and rumors
- Illumina recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Illumina guidance history: guided vs reported
- Illumina gross margin by quarter
- Illumina operating margin by quarter
- Illumina net income by quarter
- Illumina free cash flow by quarter
- Illumina R&D spending by quarter
- Illumina capital expenditures by quarter
- Illumina Total product revenue revenue by quarter
- Illumina Service revenue by quarter